OPIOID DRUGS MARKET ANALYSIS

Opioid Drugs Market , by Drug Type (Codeine, Fentanyl, Morphine, Hydrocodone, Oxycodone, and Others), by Application (Analgesia, Cough Suppression, and Diarrhea Suppression), by Route of Administration (Oral, Topical, Parenteral, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Sep 2023
Code : CMI1017
Pages :203
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Opioid Drugs Market: Key Developments

In August 2020, the U.S. Food and Drug Administration (FDA) announced that they had approved Olinvyk (oliceridine) an opioid agonist, for the management of moderate to severe acute pain in adults.

On May 9, 2023, Jiangsu Nhwa Pharmaceutical Co., Ltd., a china-based pharmaceutical company and a distribution partner of Trevena Inc., a U.S.-based clinical stage biopharmaceutical company, announced that they had received approval from China’s National Medical Products Administration (NMPA) for Olinvyk (oliceridine), an opioid agonist indicated to manage pain severe enough to require an intravenous opioid analgesic in adult patients whose alternative treatments are inadequate.

In August 2022, Adalvo Limited, a global pharmaceutical company, announced that they had acquired Onsolis, a fentanyl-based opioid agonist, from Aveva, a U.S.-based pharmaceutical company, for the management of chronic pain in patients recovering from surgery.